Saturday, April 4, 2020
Home Tags AIDS

Tag: AIDS

CytoDyn (OTCQB: CYDY) Experiencing Viral Boom in Enrollment May Lead to...

Miami, FL – March 23, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled...

The Great CytoDyn (OTCQB: CYDY) Bear Raid Fails to Impress

Miami, FL – February 10, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled...

CytoDyn (OTCQB: CYDY) Files for Breakthrough Therapy Designation with the FDA...

Miami, FL – January 13, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of...

CytoDyn (OTCQB: CYDY) to Deliver Presentation at Biotech Showcase Conference

Miami, FL – January 9, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of...

Cytodyn, Inc. (OTCQB: CYDY) may have an edge over Immunomedics, Inc....

Miami, FL – December 26, 2019 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled...

CytoDyn (OTCQB: CYDY) Reports Early Results from First Patient in its...

Miami, FL – December 4, 2019 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of...

CytoDyn, Inc. (OTCQB: CYDY) Why you need to look at this...

Miami, FL - September 16, 2018 (EmergingGrowth.com NewsWire) -- EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled...

CytoDyn, Inc. (OTCQB: CYDY) Disruptive Targeting of HIV and Expands Indications...

Miami, FL - August 13, 2018 (EmergingGrowth.com NewsWire) -- EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled...

Immune Therapeutics, Inc. (OTCQB: IMUN) Drops 10.71% After Receiving NAFDAC Approval...

Immune Therapeutics, Inc. (OTCQB: IMUN) is a biopharmaceutical company, which develops treatments for diseases, such as: HIV/AIDS, cancer, other autoimmune and neurodegenerative ailments. Shares...